Metabolic profile of PML lesions in patients with and without IRIS an observational study

Neurology

Volumn 79, Issue 10, 2012, Pages 1041-1048

  Gheuens, Sarah ^a,b   Ngo, Long ^c   Wang, Xiaoen ^d   Alsop, David C ^d   Lenkinski, Robert E ^d   Koralnik, Igor J ^a,b,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Division of Viral Pathogenesis   (United States)

^c Department of Medicine ^*  (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE; CREATINE; CYTARABINE; INOSITOL; LACTIC ACID; LIPID; MEFLOQUINE; MIRTAZAPINE; N ACETYLASPARTIC ACID; NATALIZUMAB; RECOMBINANT INTERLEUKIN 2;

AMINO ACID BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LABORATORY TEST; LIPID BLOOD LEVEL; METABOLISM; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTON NUCLEAR MAGNETIC RESONANCE; SURVIVOR;

EID: 84866118855     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318268465b     Document Type: Article

References (37)

1. Tan K, Roda R, Ostrow L, McArthur J, Nath A. PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology 2009;72:1458-1464.
2. Tan IL, McArthur JC, Clifford DB, Major EO, Nath A. Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology 2011;77:1061-1067.
3. Wenning W, Haghikia A, Laubenberger J, et al. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med 2009;361:1075-1080.
4. Vendrely A, Bienvenu B, Gasnault J, Thiebault JB, Salmon D, Gray F. Fulminant inflammatory leukoencephalopathy associated with HAART-induced immune restoration in AIDS-related progressive multifocal leukoencephalopathy. Acta Neuropathol 2005;109:449-455.
5. Gheuens S, Bord E, Kesari S, et al. Role of CD4 and CD8 T-cell responses against JC virus in the outcome of patients with progressive multifocal leukoencephalopathy (PML) and PML with Immune reconstitution inflammatory syndrome. J Virol 2011;85:7256-7263.
6. Johnson T, Nath A. Neurological complications of immune reconstitution in HIV-infected populations. Ann NY Acad Sci 2010;1184:106-120.
7. Katz-Brull R, Lenkinski RE, Du Pasquier RA, Koralnik IJ. Elevation of myoinositol is associated with disease containment in progressive multifocal leukoencephalopathy. Neurology 2004;63:897-900.
8. Cinque P, Koralnik IJ, Clifford DB. The evolving face of human immunodeficiency virus-related progressive multifocal leukoencephalopathy: defining a consensus terminology. J Neurovirol 2003;9(suppl 1):88-92.
9. Marzocchetti A, Tompkins T, Clifford DB, et al. Determinants of survival in progressive multifocal leukoencephalopathy. Neurology 2009;73:1551-1558.
10. Elphick GF, Querbes W, Jordan JA, et al. The human polyomavirus, JCV, uses serotonin receptors to infect cells Science 2004;306:1380-1383.
11. Brickelmaier M, Lugovskoy A, Kartikeyan R, et al. Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob Agents Chemother 2009;53:1840-1849.
12. Aksamit AJ. Treatment of non-AIDS progressive multifocal leukoencephalopathy with cytosine arabinoside. J Neurovirol 2001;7:386-390.
13. Harrison DM, Newsome SD, Skolasky RL, McArthur JC, Nath A. Immune reconstitution is not a prognostic factor in progressive multifocal leukoencephalopathy. J Neuroimmunol 2011;238:81-86.
14. Delikatny EJ, Chawla S, Leung DJ, Poptani H. MR-visible lipids and the tumor microenvironment. NMR Biomed 2011;24:592-611.
15. Cuvinciuc V, Martin-Blondel G, Marchou B, Bonneville F. Proton MR spectroscopy of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome. AJNR Am J Neuroradiol 2010;31:E69 - E71.
16. Gheuens S, Smith DR, Wang X, Alsop DC, Lenkinski RE, Koralnik IJ. Simultaneous PML-IRIS after discontinuation of natalizumab in an MS patient. Neurology 2012;78:1390-1393.
17. Koopmans RA, Li DK, Zhu G, Allen PS, Penn A, Paty DW. Magnetic resonance spectroscopy of multiple sclerosis: in-vivo detection of myelin breakdown products. Lancet 1993;341:631-632.
18. Bitsch A, Bruhn H, Vougioukas V, et al. Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy. AJNR Am J Neuroradiol 1999;20:1619-1627.
19. De Stefano N, Matthews PM, Antel JP, Preul M, Francis G, Arnold DL. Chemical pathology of acute demyelinating lesions and its correlation with disability. Ann Neurol 1995;38:901-909.
20. Kuker W, Ruff J, Gaertner S, Mehnert F, Mader I, Nagele T. Modern MRI tools for the characterization of acute demyelinating lesions: value of chemical shift and diffusion-weighted imaging. Neuroradiology 2004;46:421-426.
21. Gabis LV, Panasci DJ, Andriola MR, Huang W. Acute disseminated encephalomyelitis: an MRI/MRS longitudinal study. Pediatr Neurol 2004;30:324-329.
22. Harting I, Hartmann M, Jost G, et al. Differentiating primary central nervous system lymphoma from glioma in humans using localised proton magnetic resonance spectroscopy. Neurosci Lett 2003;342:163-166.
23. Burtscher IM, Skagerberg G, Geijer B, Englund E, Stahlberg F, Holtas S. Proton MR spectroscopy and preoperative diagnostic accuracy: an evaluation of intracranial mass lesions characterized by stereotactic biopsy findings. AJNR Am J Neuroradiol 2000;21:84-93.
24. 1H magnetic resonance spectroscopy of primary human and murine cells of the myeloid lineage. Immunomethods 1994;4:188-198.
25. 1H NMR studies of membrane changes during the activation of primary T lymphocytes. Immunomethods 1994;4:127-138.
26. 1H-MR spectroscopy for metabolic characterisation of diffuse and focal brain lesions in patients infected with HIV. J Neurol Neurosurg Psychiatry 1998;64:516-523.
27. 1H-MR spectroscopy in clinically isolated syndromes suggestive of multiple sclerosis: correlation between metabolic alterations and diagnostic MR imaging criteria. J Neurol 2008;255:56-63.
28. 1H-MRS for the diagnosis of acute disseminated encephalomyelitis: insight into the acutedisease stage. Pediatr Radiol 2010;40:106-113.
29. 1H-magnetic resonance spectroscopy study. J Neurol Sci 2001;182:143-150.
30. Sastre-Garriga J, Ingle GT, Chard DT, et al. Metabolite changes in normal-appearing gray and white matter are linked with disability in early primary progressive multiple sclerosis. Arch Neurol 2005;62:569-573.
31. Rigotti DJ, Gonen O, Grossman RI, et al. Global N-acetylaspartate declines even in benign multiple sclerosis. AJNR Am J Neuroradiol 2011;32:204-209.
32. Zaaraoui W, Reuter F, Rico A, et al. Occurrence of neuronal dysfunction during the first 5 years of multiple sclerosis is associated with cognitive deterioration. J Neurol 2011;258:811-819.
33. Aboul-Enein F, Krssak M, Hoftberger R, Prayer D, Kristoferitsch W. Reduced NAA-levels in the NAWM of patients with MS is a feature of progression: a study with quantitative magnetic resonance spectroscopy at 3 Tesla. PLoS One 2010;5:e11625.
34. Arnold DL, Matthews PM, Francis GS, O'Connor J, Antel JP. Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques. Ann Neurol 1992;31:235-241.
35. Brenner RE, Munro PM, Williams SC, et al. The proton NMR spectrum in acute EAE: the significance of the change in the Cho:Cr ratio. Magn Reson Med 1993;29:737-745.
36. Tartaglia MC, Narayanan S, De Stefano N, et al. Choline is increased in pre-lesional normal appearing white matter in multiple sclerosis. J Neurol 2002;249:1382-1390.
37. Marzocchetti A, Di Giambenedetto S, Cingolani A, Ammassari A, Cauda R, De Luca A. Reduced rate of diagnostic positive detection of JC virus DNA in cerebrospinal fluid in cases of suspected progressive multifocal leukoencephalopathy in the era of potent antiretroviral therapy. J Clin Microbiol 2005;43:4175-4177.